Education
About Us
Working with TipRanks
Follow Us
Genomma Lab Internacional SAB de CV Class B (DE:GEKA)
:GEKA
RESEARCH TOOLSreports
GEKA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.79 - €1.35
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€968.47M
Enterprise ValueN/A
Total Cash (Recent Filing)€2.38B
Total Debt (Recent Filing)$5.06B
Price to Earnings (P/E)8.1
Beta0.52
Next Earnings
Jul 23, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 13, 2025Dividend Yield4.47%
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,000,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio0.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genomma Lab Internacional SAB de CV News
PremiumCompany Announcements
Genomma Lab Reports Strong Q1 2025 Performance
PremiumCompany Announcements
Genomma Lab Reports Strong 2024 Financial Results
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.44%
Mutual Funds
<0.01% Other Institutional Investors
94.56% Public Companies and
Individual Investors
GEKA FAQ
What was Genomma Lab Internacional SAB de CV Class B’s price range in the past 12 months?
Genomma Lab Internacional SAB de CV Class B lowest stock price was €0.79 and its highest was €1.35 in the past 12 months.
What is Genomma Lab Internacional SAB de CV Class B’s market cap?
Genomma Lab Internacional SAB de CV Class B’s market cap is €968.47M.
When is Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date?
Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date is Jul 23, 2025 which is in 59 days.
How were Genomma Lab Internacional SAB de CV Class B’s earnings last quarter?
Genomma Lab Internacional SAB de CV Class B released its earnings results on Apr 30, 2025. The company reported €0.023 earnings per share for the quarter, beating the consensus estimate of €0.019 by €0.003.
Is Genomma Lab Internacional SAB de CV Class B overvalued?
According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued.
Does Genomma Lab Internacional SAB de CV Class B pay dividends?
Genomma Lab Internacional SAB de CV Class B pays a Notavailable dividend of €0.033 which represents an annual dividend yield of 4.47%. See more information on Genomma Lab Internacional SAB de CV Class B dividends here
What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?
Genomma Lab Internacional SAB de CV Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?
Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.
What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?
Genomma Lab Internacional SAB de CV Class B reported an EPS of €0.023 in its last earnings report, beating expectations of €0.019. Following the earnings report the stock price went down -5.607%.
Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?
Currently, no hedge funds are holding shares in DE:GEKA
Company Description
Genomma Lab Internacional SAB de CV Class B
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
GEKA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong sales growth, improved margins, and record cash flow generation. Challenges persist in specific segments and markets, but overall performance exceeded expectations.Read More>